Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1 -Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study.
Zhe HuangHuan YanLiang ZengQinqin XuWenhuan GuoShaoding LinWenjuan JiangZhan WangLi DengHaoyue QinXing ZhangFan TongRuiguang ZhangZhaoyi LiuLin ZhangXiaorong DongNong YangYong-Chang ZhangPublished in: JCO precision oncology (2023)
-rearranged NSCLCs benefit from ICI plus chemotherapy in any treatment setting, including patients who present with brain metastasis.